Kura Oncology (KURA) Financials: History & Chart

Kura Oncology, Inc.(KURA)

Biotechnology · San Diego, CA

$10.47-0.15 (-1.41%)

Delayed quote: Oct 6, 2026, 10:45 AM EDT

About Kura Oncology, Inc.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

San Diego, CA

260 employees

kuraoncology.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Troy Wilson

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	77.22M	20.87M	18.27M	17.34M	20.75M	15.29M	14.11M	53.88M	0.00
Cost of Goods Sold	4.07M	243K	617K	0.00	3.21M	0.00	0.00	0.00	0.00
Gross Profit	73.15M	20.63M	17.65M	17.34M	17.54M	15.29M	14.11M	53.88M	0.00
Gross Profit Margin	94.7%	98.8%	96.6%	100.0%	84.5%	100.0%	100.0%	100.0%	N/A
Total Operating Expenses	391.24M	93.64M	96.46M	103.60M	97.53M	87.95M	78.81M	76.34M	59.88M
Research & Development	259.47M	61.89M	65.26M	64.41M	67.91M	62.78M	55.97M	52.27M	41.70M
Selling, General & Administrative	134.93M	31.75M	31.20M	39.14M	32.84M	25.17M	22.84M	24.07M	18.18M
Operating Income (EBIT)	-318.09M	-73.01M	-78.81M	-86.27M	-80.00M	-72.67M	-64.70M	-22.45M	-59.88M
Operating Margin	-411.9%	-349.8%	-431.5%	-497.6%	-385.5%	-475.3%	-458.6%	-41.7%	N/A
Income Before Tax (EBT)	-296.69M	-68.32M	-73.33M	-80.93M	-74.12M	-66.12M	-57.20M	-17.20M	-54.40M
Interest Income	17.79M	N/A	5.83M	5.69M	6.27M	6.93M	7.88M	5.66M	5.89M
Interest Expense	1.42M	345K	336K	346K	393K	391K	382K	403K	412K
Other Income/Expense	21.40M	4.69M	5.49M	5.34M	5.88M	6.54M	7.50M	5.26M	5.48M
Net Income	-296.77M	-68.33M	-73.33M	-81.00M	-74.12M	-66.12M	-57.43M	-19.22M	-54.40M
Income Tax Expense	84K	5K	8K	71K	0.00	0.00	226K	2.02M	0.00
Net Profit Margin	-384.3%	-327.3%	-401.5%	-467.2%	-357.2%	-432.5%	-407.1%	-35.7%	N/A
EBITDA	-314.80M	-70.64M	-78.46M	-85.86M	-79.83M	-72.44M	-64.46M	-22.25M	-59.68M
EBITDA Margin	-407.6%	-338.4%	-429.6%	-495.3%	-384.7%	-473.8%	-456.9%	-41.3%	N/A
Depreciation & Amortization	3.29M	2.37M	355K	403K	164K	224K	241K	204K	208K
EPS Basic	-3.37	-0.77	-0.83	-0.92	-0.85	-0.75	-0.66	-0.22	-0.63
EPS Diluted	-3.37	-0.77	-0.83	-0.92	-0.85	-0.75	-0.66	-0.22	-0.63
Weighted Average Basic Shares	88.86M	88.86M	88.61M	88.05M	87.64M	87.59M	87.42M	87.14M	86.95M
Weighted Average Diluted Shares	88.86M	88.86M	88.61M	88.05M	87.64M	87.59M	87.42M	87.14M	86.95M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	67.48M	53.88M	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Goods Sold	57K	0.00	849K	0.00	0.00	194K	0.00	10K
Gross Profit	67.42M	53.88M	-849K	0.00	0.00	-194K	0.00	-10K
Gross Profit Margin	99.9%	100.0%	N/A	N/A	N/A	N/A	N/A	N/A
Total Operating Expenses	371.06M	247.08M	164.96M	139.87M	131.26M	91.70M	67.48M	62.88M
Research & Development	251.07M	169.97M	115.23M	92.81M	84.72M	60.40M	47.83M	46.79M
Selling, General & Administrative	119.98M	77.11M	50.57M	47.05M	46.54M	31.31M	19.65M	16.10M
Operating Income (EBIT)	-303.63M	-193.19M	-165.80M	-139.87M	-131.26M	-91.90M	-67.48M	-62.88M
Operating Margin	-449.9%	-358.5%	N/A	N/A	N/A	N/A	N/A	N/A
Income Before Tax (EBT)	-278.37M	-171.97M	-152.63M	-135.84M	-130.47M	-89.63M	-63.14M	-60.45M
Interest Income	26.77M	22.85M	14.72M	4.25M	1.21M	2.80M	4.67M	3.17M
Interest Expense	1.51M	1.62M	1.55M	229K	414K	578K	580K	970K
Other Income/Expense	25.26M	21.23M	13.17M	4.03M	792K	2.27M	4.44M	2.64M
Net Income	-278.67M	-173.98M	-152.63M	-135.84M	-130.47M	-89.63M	-63.14M	-60.45M
Income Tax Expense	297K	2.02M	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-412.9%	-322.9%	N/A	N/A	N/A	N/A	N/A	N/A
EBITDA	-302.60M	-192.35M	-164.96M	-139.11M	-130.70M	-91.70M	-67.47M	-62.87M
EBITDA Margin	-448.4%	-357.0%	N/A	N/A	N/A	N/A	N/A	N/A
Depreciation & Amortization	1.03M	848K	849K	759K	558K	194K	10K	10K
EPS Basic	-3.18	-2.02	-2.08	-2.03	-1.97	-1.69	-1.51	-1.72
EPS Diluted	-3.18	-2.02	-2.08	-2.03	-1.97	-1.69	-1.51	-1.72
Weighted Average Basic Shares	87.68M	86.16M	73.23M	66.99M	66.35M	53.08M	41.95M	35.19M
Weighted Average Diluted Shares	87.68M	86.16M	73.23M	66.99M	66.35M	53.08M	41.95M	35.19M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.